Rosiglitazone (RSG), the thiazolidinedione compound that is well known to improve insulin resistance through regulating adiponectin gene expression, and used for the treatment of type-2 diabetes mellitus [22], is considered as a transcription factor peroxisome proliferator-activated receptor (PPARγ) agonist [23, 24]. This evidence concerns the gene PPARG and Insulin resistance.